Back to Screener

Sensus Healthcare, Inc (SRTS)

Price$4.44

Favorite Metrics

Price vs S&P 500 (26W)26.16%
Price vs S&P 500 (4W)10.80%
Market Capitalization$73.91M
P/E Ratio (Annual)9.63x

All Metrics

P/CF (Annual)139.99x
Book Value / Share (Quarterly)$2.92
P/TBV (Annual)2.57x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-14.86%
Cash Flow / Share (Quarterly)$0.02
Price vs S&P 500 (YTD)10.17%
Gross Margin (TTM)43.18%
Net Profit Margin (TTM)-28.09%
EPS (TTM)$-0.47
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-0.47
Revenue Growth (5Y)23.46%
EPS (Annual)$-0.47
ROI (Annual)-16.05%
Gross Margin (Annual)43.18%
Net Profit Margin (5Y Avg)11.90%
Cash / Share (Quarterly)$1.34
Revenue Growth QoQ (YoY)-62.20%
P/E Normalized (Annual)9.63x
ROA (Last FY)-14.55%
Revenue Growth TTM (YoY)-34.27%
EBITD / Share (TTM)$-0.61
ROE (5Y Avg)12.62%
Operating Margin (TTM)-37.50%
Cash Flow / Share (Annual)$0.02
P/B Ratio1.54x
P/B Ratio (Quarterly)1.36x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.89x
Net Interest Coverage (TTM)-100.00x
ROA (TTM)-13.40%
EV / EBITDA (TTM)18.75x
EPS Incl Extra (Annual)$-0.47
Current Ratio (Annual)9.72x
Quick Ratio (Quarterly)6.31x
3-Month Avg Trading Volume0.08M
52-Week Price Return-6.26%
EV / Free Cash Flow (Annual)156.12x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.72
P/S Ratio (Annual)2.69x
Asset Turnover (Annual)0.52x
52-Week High$5.92
Operating Margin (5Y Avg)5.76%
EPS Excl Extra (Annual)$-0.47
CapEx CAGR (5Y)-11.45%
Tangible BV CAGR (5Y)33.89%
26-Week Price Return30.14%
Quick Ratio (Annual)6.31x
13-Week Price Return-2.60%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.72x
Enterprise Value$51.832
Revenue / Share Growth (5Y)23.62%
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)17.51%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.06x
Pretax Margin (Annual)-35.02%
Cash / Share (Annual)$1.34
3-Month Return Std Dev69.41%
Gross Margin (5Y Avg)57.72%
Net Income / Employee (TTM)$-0
ROE (Last FY)-16.05%
Net Interest Coverage (Annual)-27.22x
EPS Basic Excl Extra (Annual)$-0.47
P/FCF (TTM)13.74x
Receivables Turnover (TTM)2.13x
EV / Free Cash Flow (TTM)156.12x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.47
Receivables Turnover (Annual)2.13x
ROI (TTM)-15.11%
P/S Ratio (TTM)2.69x
Pretax Margin (5Y Avg)13.47%
Revenue / Share (Annual)$1.68
Tangible BV / Share (Annual)$2.93
Price vs S&P 500 (52W)-36.09%
Year-to-Date Return12.81%
5-Day Price Return0.45%
EPS Normalized (Annual)$-0.47
ROA (5Y Avg)10.51%
Net Profit Margin (Annual)-28.09%
Month-to-Date Return12.81%
Cash Flow / Share (TTM)$-0.04
EBITD / Share (Annual)$-0.61
EPS Growth (3Y)17.62%
Operating Margin (Annual)-37.50%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)139.99x
ROI (5Y Avg)12.62%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.47
P/TBV (Quarterly)1.00x
P/B Ratio (Annual)1.36x
Inventory Turnover (TTM)1.06x
Pretax Margin (TTM)-35.02%
Book Value / Share (Annual)$2.92
Price vs S&P 500 (13W)-3.29%
Beta1.34x
P/FCF (Annual)222.63x
Revenue / Share (TTM)$1.68
ROE (TTM)-15.11%
52-Week Low$3.03

Analyst Recommendations

Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.10

Industry Peers — Surgical & Medical Instruments(108)

SymbolP/S Ratio (TTM)Revenue Growth (5Y)Gross Margin (TTM)Operating Margin (TTM)Price
SRTSSensus Healthcare, Inc
2.69x23.46%43.18%-37.50%$4.44
SYKStryker Corporation
5.15x11.84%64.57%19.43%$338.38
BSXBoston Scientific Corp.
4.76x15.16%69.01%18.00%$63.42
MMM3M Company
3.18x-4.97%39.92%18.55%$150.55
MDLNMedline Inc. Class A common stock
2.21x26.44%7.78%$46.94
BDXBecton, Dickinson and Co.
2.01x6.32%46.42%12.15%$154.82
RMDResMed Inc.
6.06x11.72%60.85%33.70%$224.72
DXCMDexCom, Inc.
5.23x19.33%62.09%19.56%$61.23
WSTWest Pharmaceutical Services, Inc.
6.22x7.44%35.91%19.03%$269.81
PODDInsulet Corporation
5.31x24.53%71.63%12.92%$201.47
PENPenumbra, Inc.
9.31x20.16%67.14%13.48%$331.47

About

Sensus Healthcare manufactures superficial radiotherapy (SRT) systems for treating skin cancers and non-cancerous skin conditions. The company's products, including the SRT-100 and SRT-100 Vision platforms, address dermatological applications such as basal cell carcinoma, squamous cell carcinoma, and keloids. Revenue is generated primarily from U.S. customers.